NEW YORK Johnson & Johnson has confirmed a review of its pharmaceuticals business.
Marc Monseau, a J&J rep, issued this statement late Friday: “As part of our ongoing efforts to leverage the best creative talent in advertising and marketing and to enhance efficiencies through a more integrated approach, we are undertaking a review of the creative and marketing agencies that support our pharmaceuticals group. It is premature to say what the outcome will be.”
He declined to discuss the matter in detail with Adweek.
The group includes Procrit, Topomax and Ultram, and estimated annual marketing support likely tops $100 million.
Agency assignments could not be immediately determined, nor could a timeline for the process.